Eli Lilly (LLY) Accumulated Expenses (2009 - 2026)

Eli Lilly has reported Accumulated Expenses for 18 years, with the latest figure at $1.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 22.0% year-over-year to $1.4 billion; the trailing twelve-month figure through Mar 2026 stood at $1.4 billion (up 22.0% YoY), and the FY2025 full-year result was $2.4 billion, up 13.42% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $1.4 billion, down from $2.4 billion in the prior quarter.
• The five-year high for Accumulated Expenses was $2.4 billion in Q4 2025, with the low at $693.1 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $1.3 billion across 5 years, with a median of $1.2 billion in 2024.
• The largest YoY upside for Accumulated Expenses was 55.73% in 2023 against a maximum downside of 3.82% in 2023.
• Eli Lilly's Accumulated Expenses stood at $1.1 billion in 2022, then surged by 55.73% to $1.7 billion in 2023, then grew by 26.88% to $2.1 billion in 2024, then climbed by 13.42% to $2.4 billion in 2025, then tumbled by 42.78% to $1.4 billion in 2026.
• The last three Accumulated Expenses figures came in at $1.4 billion (Q1 2026), $2.4 billion (Q4 2025), and $2.0 billion (Q3 2025), per Business Quant data.